• About us
  • Contact us
  • Our team
  • Terms of Service
Saturday, November 14, 2026
Kashmir Images - Latest News Update
Epaper
  • TOP NEWS
  • CITY & TOWNS
  • LOCAL
  • BUSINESS
  • NATION
  • WORLD
  • SPORTS
  • OPINION
    • EDITORIAL
    • ON HERITAGE
    • CREATIVE BEATS
    • INTERALIA
    • WIDE ANGLE
    • OTHER VIEW
    • ART SPACE
  • Photo Gallery
  • CARTOON
  • EPAPER
No Result
View All Result
Kashmir Images - Latest News Update
No Result
View All Result
Home TOP NEWS

3 COVID-19 vaccines under active consideration of drug regulator: Health Ministry

Press Trust of india by Press Trust of india
December 9, 2020
in TOP NEWS
A A
0
Russia seeks collaboration with India for manufacturing COVID-19 vaccine Sputnik V: Sources
FacebookTwitterWhatsapp

New Delhi: Three COVID-19 vaccines, developed by Bharat Biotech, Serum Institute of India and Pfizer, are under active consideration of India’s drug regulator and there is hope that early licensure is possible for all or any of them, the Union health ministry said on Tuesday.

Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for their COVID-19 vaccines.

More News

Slain SPOs laid to rest with honours in Kishtwar; LG Sinha pays tributes

CAASPI delegation proposes social defence volunteer groups in J&K

CM chairs Cabinet meeting in Jammu; key proposals discussed

Load More

At a press briefing, NITI Aayog member (Health) V K Paul said the COVID-19 situation in India has stabilised.

With active cases reducing, a “clear-cut declining trend” in the pandemic is being seen even though the situation in many other countries is becoming quite serious, he said.

The concern and anxiety following an increase in daily cases of infection in Delhi also looks like to have settled, Paul added.

Asked what steps would be followed by the DCGI in the absence of a water-tight emergency use authorisation law for granting licence to vaccine makers, Union Health Secretary Rajesh Bhushan said not all countries’ regulatory framework or rules and acts mention emergency use authorisation.

“So, the fact that this phrase is not used in the national regulatory framework of any country does not mean that a specific country would not have an enabling provision to accord an approval which is early and distinct from a regular market approval.

“India’s regulatory framework has a specific provision for grant of emergency use authorisation, although this phrase is not used,” he said.

The New Drugs and Clinical Trials Rules, 2019, clearly specifies that under specific special situations, relaxation, abbreviation, omission, or deferment of data including local clinical trial data may be considered for approval.

“This is our law. Similarly, other countries too have their laws,” Bhushan said.

Giving a bird’s-eye view of the Indian landscape of COVID-19 vaccines, Bhushan mentioned that eight vaccines are at different stages of development.

One is Covishield, manufactured by Serum Institute of India in collaboration with AstraZeneca. Phase two and three clinical trials of this vaccine is underway and the firm has applied for emergency use authorisation.

Another is Covaxin, which is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and is in phase three of clinical trials. It has also applied for emergency use authorisation.

The third one is ZyCOV-D, being developed by Cadila Healthcare Ltd in Ahmedabad in collaboration with the Centre’s Department of Biotechnology and is in phase two of the trials.

The fourth vaccine candidate is Sputnik V which is being manufactured by Dr Reddy’s Lab, Hyderabad, in collaboration with Russia’s Gamaleya National Centre. The phase two trial in India is over and phase three will begin next week.

The fifth one is NVX-CoV2373, which is being developed by Serum Institute of India in collaboration with Novavax and its phase three clinical trial is under consideration with the drug regulator.

The sixth vaccine candidate is Recombinant Protein Antigen-based vaccine, to be manufactured by Biological E Ltd, Hyderabad, in collaboration with MIT, USA.      Its pre-clinical animal studies have concluded and phase one and two human clinical trials have started. Another one is HGCO 19, being manufactured by Genova in Pune in collaboration with HDT, USA. Its pre-clinical animal studies are over and phase one and two clinical trials is set to start.

The eighth vaccine is being developed by Bharat Biotech International Ltd in collaboration with Thomas Jefferson University, USA and it is at the pre-clinical stages.

“Another vaccine, which is in the initial stage, is being developed by Aurbindo Pharma. So, there are nine vaccines out of which six are in clinical trials and three are in pre-clinical stage,” Bhushan said.

“There are multiple vaccine candidates in different stages of development and some may get licensed in the next few weeks. But we cannot foretell at this moment because licensure or market authorization is the domain of the national regulator.”

Most of the vaccines are of two or three doses to be administered three to four weeks apart. However, even after vaccination, COVID precautions must be taken and this has been advised by WHO also, Bhushan said, adding, “Vaccination does not mean people become carefree.”

About cold chain infrastructure augmentation, the health secretary said presently the system consists of 85,634 equipment for storage of vaccine at about 28,947 cold chain points across the country.

“Current cold chain is capable of storing additional quantity of COVID-19 vaccine required for first the three crore — healthcare and frontline workers,” he said, adding states have collected data of frontline healthcare workers who would get the shots.

The data is being uploaded on Co-WIN software, Bhushan said.

The ministry, in consultation with states, has assessed the additional requirement for cold chain storage and the first supply of such additional equipment would begin from December 10, the health secretary said.

Bhushan said that while 2.38 lakh auxiliary nurse midwives help in vaccination under universal immunisation programme, only 1.54 lakh such health workers will be used for COVID-19 inoculation.

Additional vaccinators are being arranged in collaboration with states and UTs, he added.

Previous Post

Fruit Mandi Sopore shuts in support of farmers’ Bharat Bandh call

Next Post

90-year-old Maggie world’s first to get anti-COVID jab

Press Trust of india

Press Trust of india

Related Posts

Slain SPOs laid to rest with honours in Kishtwar; LG Sinha pays tributes

Slain SPOs laid to rest with honours in Kishtwar; LG Sinha pays tributes
November 14, 2026

Kishtwar: Hundreds of people gathered in the remote Dachhan area of Kishtwar district on Friday to bid a tearful farewell...

Read moreDetails

CAASPI delegation proposes social defence volunteer groups in J&K

CAASPI delegation proposes social defence volunteer groups in J&K
November 14, 2026

Jammu: A delegation of the Centre for Activities for Advanced, Strong and Progressive India (CAASPI), Jammu and Kashmir, on Friday...

Read moreDetails

CM chairs Cabinet meeting in Jammu; key proposals discussed

CM chairs Cabinet meeting in Jammu; key proposals discussed
November 14, 2026

Jammu: Chief Minister Omar Abdullah on Friday chaired a meeting of the Council of Ministers here to deliberate on key...

Read moreDetails

Attack on CRPF post: Several suspects picked up for questioning

Searches intensified after Kathua attack; DGP reviews ongoing operation
November 14, 2026

Srinagar: Several suspects have been picked up for questioning in the aftermath of the Kulgam attack in which three CRPF...

Read moreDetails

BJP asks Pakistan to hand over PoK, says Kashmir integral part of India

Muslims will be looked after by the Modi govt: BJP leader Shahnawaz Hussain
November 14, 2026

New Delhi: The BJP on Friday asked Pakistan to hand over Pakistan-occupied Kashmir (PoK) to India, asserting that Kashmir was,...

Read moreDetails

NC ready for any sacrifice in struggle for restoration of J&K’s rights: Farooq Abdullah

Jammu can finally look forward to comprehensive development under NC rule: Farooq Abdullah
November 14, 2026

Srinagar: National Conference president Farooq Abdullah on Friday said his party is ready to make any sacrifice in the struggle...

Read moreDetails
Next Post
90-year-old Maggie world’s first to get anti-COVID jab

90-year-old Maggie world's first to get anti-COVID jab

  • About us
  • Contact us
  • Our team
  • Terms of Service
E-Mailus: kashmirimages123@gmail.com

© 2025 Kashmir Images - Designed by GITS.

No Result
View All Result
  • TOP NEWS
  • CITY & TOWNS
  • LOCAL
  • BUSINESS
  • NATION
  • WORLD
  • SPORTS
  • OPINION
    • EDITORIAL
    • ON HERITAGE
    • CREATIVE BEATS
    • INTERALIA
    • WIDE ANGLE
    • OTHER VIEW
    • ART SPACE
  • Photo Gallery
  • CARTOON
  • EPAPER

© 2025 Kashmir Images - Designed by GITS.